share_log

Regulus Therapeutics Q2 EPS $(0.17) Misses $(0.13) Estimate

Benzinga ·  Aug 8 16:34

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 54.05 percent increase over losses of $(0.37) per share from the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment